Treatment

CG Christina Guttmann-Gruber
JH Josefina Piñón Hofbauer
BT Birgit Tockner
VR Victoria Reichl
AK Alfred Klausegger
PH Peter Hofbauer
MW Martin Wolkersdorfer
KT Khek-Chian Tham
SL Seong Soo Lim
JC John E. Common
AD Anja Diem
KU Katharina Ude-Schoder
WH Wolfgang Hitzl
FL Florian Lagler
JR Julia Reichelt
JB Johann W. Bauer
RL Roland Lang
ML Martin Laimer
ask Ask a question
Favorite

Patients were randomized into two treatment arms and instructed to apply 1 g of either verum- (active ingredient: calcipotriol 0.05 µg/g) or placebo-containing ointment topically onto two designated target wounds (≥ 6 cm2 each) daily over a period of four weeks. No other changes to standard of care of the patients were applied. Thus, while patients were instructed not to apply any other topical substances onto the designated target wounds, all other EB lesions were continued to be concurrently treated with the previous local wound dressings.

After a two-month wash out-phase, patients crossed over into the other treatment arm. Wounds were photographed, measured and swabbed for microbiome profiling at study visits (V) on day 0 (V1/V4), 14 (V2/V5) and 28 (V3/V6) during each treatment period.

Blood drawing was optional for the patient and was performed at the beginning and end of each treatment phase to assess serum calcium levels.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A